Agenus shared Bernard A. Fox’s post on LinkedIn, adding:
“Incredible work from Dr. Myriam Chalabi and colleagues, and an exciting moment for the field. We are grateful to see investigator-sponsored research like NEOASIS continue to explore the potential of immune checkpoint blockade—especially in diseases once believed to be unresponsive.
While BOT/BAL remains investigational, studies like NEOASIS highlight the dedication of clinicians working to refine combinations, identify predictive biomarkers, and expand options for patients with both MSI-H/dMMR and MSS/pMMR disease.
Thank you to Dr. Chalabi and to all investigators advancing innovation for patients.”
Bernard A. Fox, Co-founder, President, and CEO of UbiVac, shared a post on LinkedIn:
“Prof. Myriam Chalabi cancer immunotherapy expert at The Netherlands Cancer Institute
Beyond MSI-High!!!
Very cool! Saw a response in Undifferentiated pleiomorphic sarcoma – see scans
Key take-aways
- Short course neoadjuvant ICB is extremely effective in dMMR colon cancers and is associated with excellent long-term outcomes
- Optimal combinations, duration of treatment and organ preservation
- ICB is effective in a subgroup of pMMR colon cancers
- Validation of potential predictive (attainable) biomarkers in future trials
- Additional avenues →modulation
Chemotherapy
Targeting
Immunosuppression
Novel treatments - Potential neoadjuvant ICB in non-CRC dMMR and pMMR tumors ongoing.”
More posts about Agenus.
